BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
UBS
Argus Health
Johnson and Johnson
Harvard Business School
Merck
Chinese Patent Office
McKinsey
Farmers Insurance

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,883,217

« Back to Dashboard

Summary for Patent: 8,883,217
Title:Modified release formulations containing drug-ion exchange resin complexes
Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
Inventor(s): Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ)
Assignee: TRIS Pharma, Inc. (Monmouth Junction, NJ)
Application Number:14/155,410
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 8,883,217

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Tris Pharma Inc DYANAVEL XR amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 208147-001 Oct 19, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,883,217

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,597,684 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,675,703 Modified release formulations containing drug - ion exchange resin complexes ➤ Subscribe
8,062,667 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,198,864 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,675,704 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,202,537 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,747,902 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,491,935 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
8,337,890 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
9,549,989 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,883,217

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark 2428205 ➤ Subscribe
European Patent Office 2018160 ➤ Subscribe
European Patent Office 2428205 ➤ Subscribe
Spain 2378573 ➤ Subscribe
Spain 2396039 ➤ Subscribe
Israel 194042 ➤ Subscribe
Japan 2009530298 ➤ Subscribe
Japan 5479086 ➤ Subscribe
South Korea 20080108520 ➤ Subscribe
South Korea 101495146 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Queensland Health
McKesson
US Army
Citi
Deloitte
Johnson and Johnson
Daiichi Sankyo
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot